Literature DB >> 19038552

Feasibility study of radiophotoluminescent glass rod dosimeter postal dose intercomparison for high energy photon beam.

Jeong-Eun Rah1, Siyong Kim, Kwang-Ho Cheong, Jeong-Woo Lee, Jin-Beom Chung, Dong-Oh Shin, Tae-Suk Suh.   

Abstract

A radiophotoluminescent glass rod dosimeter (GRD) system has recently become commercially available. In this study we evaluated whether the GRD would be suitable for external dosimetric audit program in radiotherapy. For this purpose, we introduced a methodology of the absorbed dose determination with the GRD by establishing calibration coefficient and various correction factors (non-linearity dose response, fading, energy dependence and angular dependence). A feasibility test of the GRD postal dose intercomparison was also performed for eight high photon beams by considering four radiotherapy centers in Korea. In the accuracy evaluation of the GRD dosimetry established in this study, we obtained within 1.5% agreements with the ionization chamber dosimetry for the (60)Co beam. It was also observed that, in the feasibility study, all the relative deviations were smaller than 3%. Based on these results, we believe that the new GRD system has considerable potential to be used for a postal dose audit program.

Entities:  

Mesh:

Year:  2008        PMID: 19038552     DOI: 10.1016/j.apradiso.2008.09.018

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  2 in total

Review 1.  Quality assurance for clinical trials.

Authors:  Geoffrey S Ibbott; Annette Haworth; David S Followill
Journal:  Front Oncol       Date:  2013-12-19       Impact factor: 6.244

2.  A comparison of the dose distributions between the brachytherapy 125I source models, STM1251 and Oncoseed 6711, in a geometry lacking radiation equilibrium scatter conditions.

Authors:  Kenichi Tanaka; Ken-ichi Kamo; Kunihiko Tateoka; Osamu Asanuma; Kaori Sato; Hiromitsu Takeda; Koh-ichi Sakata; Jun Takada
Journal:  J Radiat Res       Date:  2015-01-24       Impact factor: 2.724

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.